Engineering Antibody Fc to Reduce Viscosity for Subcutaneous Delivery
Time: 12:00 pm
day: Conference Day One
Details:
• Subcutaneous delivery of high-concentration antibody drug therapeutics is becoming increasingly prevalent due to several significant advantages including improved patient convenience, comfort, compliance, and healthcare cost
• Antibody self-associations through Fab-Fc interactions are likely contributing to viscosity significantly more than the literature, which is dominated by evidence of Fab-Fab interactions would suggest
• We show that applying functional Fc variants to omalizumab, known for its high viscosity, can lead to drastic increases and decreases in viscosity at high concentration
